The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac).
Please click here to read the rest of the FDA News Release.
The New York Times: Zantac Products Should Not Be Sold or Used, F.D.A. Warns, Citing Cancer Danger
Bloomberg: Zantac Makers Asked by FDA to Withdraw Drug on Cancer Concern
WebMD: FDA Requests Zantac Be Pulled From the Market
NPR: FDA Says Zantac Should Be Pulled From Market, Citing Cancer Risk
Popular Science: The FDA just pulled popular heartburn drug Zantac due to cancer risk
Apotheke Adhoc (Germany): USA: Ranitidin muss komplett zurück
